A wearable computer vision device with vibrating wristbands was shown in a randomized trial to reduce collisions for both people who are blind or those who are visually impaired and using a long cane and/or guide dog by 37 percent, compared to using other mobility aids alone. Such technology may augment safety for independent travel for these individuals.
Mark Varvares, MD, FACS, has been appointed as the next Chief of the Departments of Otolaryngology-Head and Neck Surgery (OHNS) at Mass Eye and Ear and Massachusetts General Hospital (MGH) and as Chair of the Department of OHNS at Harvard Medical School (HMS), following an extensive year-long search process
Sleep disorders are associated with significantly higher rates of health care utilization, conservatively placing an additional $94.9 billion in costs each year to the U.S. health care system, according to a new study from researchers at Mass Eye and Ear, a member hospital of Mass General Brigham.
Michael S. Gilmore, PhD, a renowned microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear, a member hospital of Mass General Brigham, following an extensive search.
In the largest genome-wide association study of glaucoma to date, an international team of researchers compared the genes of 34,179 people with the disease to 349,321 control subjects. They identified 127 genes linked to glaucoma, including 44 new gene loci and confirmed 83 previously reported loci.
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. In data released in preprint, two AAVCOVID vaccine candidates led to robust neutralizing antibody responses in mouse and nonhuman primate models from only a single dose. The candidates were also shown to be safe and well-tolerated in both models.
Dr. Mary Beth Cunnane, a radiologist who specializes in the imaging of patients with diseases of the eyes, ears, nose and head and neck, has been appointed Chief of Radiology at Mass Eye and Ear in Boston.
A new randomized controlled trial has found antibiotics are not necessary after routine sinus surgery for preventing infection and optimizing patient outcomes.
Proof-of-concept study represents first successful attempt to reverse the aging clock in animals through epigenetic reprogramming.
Hearing experts advocate in The New England Journal of Medicine for the FDA to implement the Over-the-Counter Hearing Aid Act of 2017. The FDA missed the deadline to release the much-anticipated regulations on August 18, 2020
Mass Eye and Ear is proud to announce the successful conclusion of its historic campaign, “Bold Science. Life-Changing Cures.” which raised $252M from philanthropy to advance research to treat and cure diseases of vision, hearing, and the head and neck. The campaign was led by co-chair Wyc Grousbeck, Boston Celtics CEO and Lead Owner and former Chairman of Mass Eye and Ear.
Researchers at Mass Eye and Ear have developed a unique diagnostic tool called DystoniaNet that uses artificial intelligence to detect dystonia from MRI scans in 0.36 seconds. DystoniaNet is the first technology of its kind to provide an objective diagnosis of the disorder. In a new study of 612 brain MRI scans, the platform diagnosed dystonia with 98.8 percent accuracy.
Mass Eye and Ear has received a five-year, $4 Million gift from Good Ventures to spur Dr. Joseph F. Arboleda-Velásquez's groundbreaking work into Alzheimer’s disease genetic resistance. This transformational gift will enable Dr. Arboleda-Velásquez to build upon the recent discovery of a genetic mutation that protected a woman who had a high familial risk for the condition and amyloid plaque deposits in her brain against early-onset Alzheimer’s.
Surgeons at Mass Eye and Ear have replaced the ocular surface of four patients who each experienced chemical burns to one eye by using their own stem cells taken from the other healthy eye, in a technique known as “cultivated autologous limbal epithelial cell transplantation” (CALEC). These four cases, all part of an ongoing clinical trial supported by the National Eye Institute of the NIH, represent the first procedures of their kind to occur in the United States.
In a new study of human ear tissues, hearing scientists have demonstrated that age-related hearing loss, also called presbycusis, is mainly caused by damage to hair cells, the sensory cells in the inner ear that transform sound-induced vibrations into the electrical signals that are relayed to the brain by the auditory nerve. Their research challenges the prevailing view of the last 60 years that age-related hearing loss is mainly driven by damage to the stria vascularis, the cellular “battery” that powers the hair cell’s mechanical-to-electrical signal conversion.
Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.
Children who choke when they drink or eat may have what’s known as dysphagia, or a swallowing disorder -- one of the most common medical complaints seen in young children. A new study has found that by combining different medical disciplines in one center rather than a typical care journey making appointments one specialist at a time, children had better outcomes, reduced the number of procedures needed, and health care costs were reduced.
The internationally-renowned Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham. AAVCOVID is a unique gene-based vaccine candidate designed to protect against SARS-CoV-2, the virus that causes COVID-19.
AveXis, will lead the manufacturing efforts of the new AAVCOVID vaccine, utilizing its cutting-edge AAV technology for treatment of rare and life-threatening neurological genetic diseases. AveXis has the option to manufacture the AAV vaccine for additional clinical development, registration and/or commercial activities.
The AAVCOVID vaccine program at Massachusetts Eye and Ear and Massachusetts General Hospital has entered into manufacturing agreements with Viralgen, Aldevron and Catalent in order to support manufacturing of the experimental vaccine for clinical studies in the second half of 2020.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right